# Plain Language Summary: Medicare IVIG Access Enhancement Act of 2025

This bill expands Medicare coverage to allow more patients to receive a treatment called IVIG (intravenous immune globulin) at home instead of having to go to a hospital or clinic. IVIG is a blood product that helps boost the immune system and is used to treat certain serious conditions. Currently, Medicare covers at-home IVIG only for people with primary immune deficiency diseases—conditions where the immune system doesn't work properly from birth or early in life. Starting January 1, 2027, this bill would expand that coverage to also include people with two additional conditions: chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). Both of these are rare neurological diseases where the immune system mistakenly attacks nerve cells, causing weakness and numbness.

The practical benefit for patients is significant: instead of traveling to a medical facility multiple times a month for treatment, eligible patients could receive their IVIG infusions in the comfort of their own homes. This saves time, reduces travel burden, and can improve quality of life for people managing chronic conditions. The bill also gives Medicare flexibility to adjust payment rates depending on which condition is being treated, recognizing that different treatments might have different costs or complexity.

For the roughly 60,000 Americans living with CIDP and MMN, this could be life-changing. Many of these patients struggle with mobility and fatigue, making frequent trips to medical facilities difficult. By bringing treatment home, the bill removes a major barrier to getting the care they need. The change takes effect in 2027, giving Medicare time to prepare and set up the necessary payment structures and oversight.

Medicare IVIG Access Enhancement Act of 2025

Smith, Adrian

Medicare IVIG Access Enhancement Act of 2025This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)